Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 16, Pages 8786
Publisher
MDPI AG
Online
2021-08-17
DOI
10.3390/ijms22168786
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial
- (2021) Naoto Katakami et al. Cardiovascular Diabetology
- Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
- (2021) Seshagiri Rao Nandula et al. Cardiovascular Diabetology
- Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
- (2021) Sin-Hee Park et al. Cardiovascular Diabetology
- Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
- (2021) Andrei C. Sposito et al. Cardiovascular Diabetology
- Inhibition of SGLT-2 rescues bone marrow cell traffic for vascular repair. Role of glucose control and ketogenesis
- (2021) Mattia Albiero et al. DIABETES
- Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species
- (2021) Xiaoling Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension
- (2020) Biswajit Chowdhury et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
- (2020) Sin-Hee Park et al. Cardiovascular Diabetology
- Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells
- (2020) Yinuo Lin et al. EBioMedicine
- Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress
- (2020) Panagiota Efstathia Nikolaou et al. ANTIOXIDANTS & REDOX SIGNALING
- Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
- (2020) Byambasuren Ganbaatar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes
- (2020) Takehiro Hashikata et al. HEART AND VESSELS
- Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
- (2020) Ignatios Ikonomidis et al. Journal of the American Heart Association
- Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
- (2020) Ghazaleh Behnammanesh et al. Redox Biology
- SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
- (2020) Martin R. Cowie et al. Nature Reviews Cardiology
- Dapagliflozin Promotes Neovascularization by Improving Paracrine Function of Skeletal Muscle Cells in Diabetic Hindlimb Ischemia Mice Through PHD2/HIF-1α Axis
- (2020) Dyah Ari Nugrahaningrum et al. Frontiers in Pharmacology
- Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
- (2020) Laween Uthman et al. CARDIOVASCULAR DRUGS AND THERAPY
- Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study
- (2020) Kazuomi Kario et al. Journal of Clinical Hypertension
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes
- (2020) Margaret Nalugo et al. VASCULAR MEDICINE
- Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis
- (2020) Yingxiu Kang et al. VASCULAR PHARMACOLOGY
- Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
- (2020) Volker Vallon et al. Annual Review of Physiology
- The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion
- (2020) Sergiy Sukhanov et al. CELLULAR SIGNALLING
- Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
- (2020) Rio P. Juni et al. KIDNEY INTERNATIONAL
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
- (2019) Agnes Bosch et al. Cardiovascular Diabetology
- SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
- (2019) Damilola D. Adingupu et al. Cardiovascular Diabetology
- Angiotensin II‐induced redox‐sensitive SGLT1 and 2 expression promotes high glucose‐induced endothelial cell senescence
- (2019) Sonia Khemais‐Benkhiat et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
- (2019) Scott Cooper et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
- (2019) Ghazaleh Behnammanesh et al. Frontiers in Pharmacology
- Smooth Muscle Cell Phenotypic Diversity
- (2019) Mingjun Liu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
- (2019) Akira Sezai et al. Cardiovascular Diabetology
- Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice
- (2019) Kentaro Mori et al. Cardiovascular Diabetology
- The effects of dapagliflozin on systemic and renal vascular function display an epigenetic signature
- (2019) Anna Solini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of ticagrelor, empagliflozin and tamoxifen against experimentally-induced vascular reactivity defects in rats in vivo and in vitro
- (2019) Yasmin Moustafa Ahmed et al. Pharmacological Reports
- Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study
- (2019) Mayu Tochiya et al. Journal of Diabetes Investigation
- SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice
- (2019) Rebeca Ortega et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial
- (2019) Atsushi Tanaka et al. DIABETES CARE
- Vascular Endothelial Cell Biology: An Update
- (2019) Krüger-Genge et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
- (2019) Yusaku Mori et al. Cardiovascular Diabetology
- Effect of empagliflozin on brachial artery shear stress and endothelial function in subjects with type 2 diabetes: Results from an exploratory study
- (2019) Concetta Irace et al. Diabetes & Vascular Disease Research
- Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
- (2019) Takahiro Sawada et al. Journal of Atherosclerosis and Thrombosis
- SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
- (2018) Dustin M. Lee et al. Cardiovascular Diabetology
- Arterial smooth muscle dynamics in development and repair
- (2018) Urmas Roostalu et al. DEVELOPMENTAL BIOLOGY
- Economic Costs of Diabetes in the U.S. in 2017
- (2018) DIABETES CARE
- The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
- (2018) Seigo Sugiyama et al. INTERNAL MEDICINE
- The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
- (2018) Hongliang Li et al. LIFE SCIENCES
- Endothelial cell dysfunction and glycocalyx – A vicious circle
- (2018) Xiaohui Zhang et al. MATRIX BIOLOGY
- Endothelial Cell Metabolism
- (2018) Guy Eelen et al. PHYSIOLOGICAL REVIEWS
- Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
- (2018) Mahmoud El-Daly et al. VASCULAR PHARMACOLOGY
- Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect
- (2018) Philipp F. Secker et al. Cell Death & Disease
- Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
- (2018) Sarah J. Mancini et al. Scientific Reports
- Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
- (2018) Hao Zhou et al. Redox Biology
- Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
- (2018) Tricia Santos Cavaiola et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells
- (2018) Kelly J. Peyton et al. BIOCHEMICAL PHARMACOLOGY
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- (2018) Annayya R. Aroor et al. Cardiovascular Diabetology
- Global trends in diabetes complications: a review of current evidence
- (2018) Jessica L. Harding et al. DIABETOLOGIA
- Effects of SGLT-2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes
- (2018) Benedetta Maria Bonora et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Central artery stiffness and thoracic aortopathy
- (2018) J. D. Humphrey et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
- (2018) Mojca Lunder et al. Cardiovascular Diabetology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
- (2017) Kosuke Kaji et al. INTERNATIONAL JOURNAL OF CANCER
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular Smooth Muscle Cells and Arterial Stiffening: Relevance in Development, Aging, and Disease
- (2017) Patrick Lacolley et al. PHYSIOLOGICAL REVIEWS
- Comparison of very long-term clinical and angiographic outcomes of bare metal stent implants between patients with and without type 2 diabetes
- (2017) Cheng-Hui Lu et al. Primary Care Diabetes
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- AFM-based detection of glycocalyx degradation and endothelial stiffening in the db/db mouse model of diabetes
- (2017) Marta Targosz-Korecka et al. Scientific Reports
- Vitamin D Receptor Activation Reduces Angiotensin-II–Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E–Knockout MiceHighlights
- (2016) Sara Martorell et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Vascular endothelium – Gatekeeper of vessel health
- (2016) Paul A. Cahill et al. ATHEROSCLEROSIS
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
- (2016) Linda A. Villani et al. Molecular Metabolism
- SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
- (2015) Ying Han et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Central Role of eNOS in the Maintenance of Endothelial Homeostasis
- (2015) Christian Heiss et al. ANTIOXIDANTS & REDOX SIGNALING
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Rodney A. Hayward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular stiffness in insulin resistance and obesity
- (2015) Guanghong Jia et al. Frontiers in Physiology
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- Arterial Stiffness as a Risk Factor for Coronary Artery Disease
- (2014) Josh Liao et al. Current Atherosclerosis Reports
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- A Ligand-Independent VEGFR2 Signaling Pathway Limits Angiogenic Responses in Diabetes
- (2014) C. M. Warren et al. Science Signaling
- Arterial Stiffness: A Nexus between Cardiac and Renal Disease
- (2014) Guanghong Jia et al. CardioRenal Medicine
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1
- (2013) Gnanapragasam Arunachalam et al. BRITISH JOURNAL OF PHARMACOLOGY
- All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database
- (2013) K. S. Taylor et al. DIABETES CARE
- Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance
- (2013) Annayya R. Aroor et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation
- (2012) Tokuo Saito et al. CARDIOVASCULAR RESEARCH
- Vascular Remodeling in Hypertension
- (2011) Ernesto L. Schiffrin HYPERTENSION
- Compound C Inhibits Vascular Smooth Muscle Cell Proliferation and Migration in an AMP-Activated Protein Kinase-Independent Fashion
- (2011) K. J. Peyton et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Dose-Dependent Modulatory Effects of Insulin on Glucose-Induced Endothelial Senescence In Vitro and In Vivo: A Relationship between Telomeres and Nitric Oxide
- (2011) H. Matsui-Hirai et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Arterial Stiffness and Cardiovascular Events
- (2010) Gary F. Mitchell et al. CIRCULATION
- Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus
- (2010) L. N. Broekhuizen et al. DIABETOLOGIA
- The global burden of diabetes and its complications: an emerging pandemic
- (2010) Dieren Susan van et al. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction
- (2009) Jian Xu et al. CIRCULATION
- Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of endothelial nitric oxide synthase and endothelial progenitor cells
- (2009) Jinglian Yan et al. JOURNAL OF VASCULAR SURGERY
- Vascular endothelial senescence: from mechanisms to pathophysiology
- (2008) Jorge D. Erusalimsky JOURNAL OF APPLIED PHYSIOLOGY
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started